Wolfgang C. Winkelmayer, MD, ScD
Publication Details
-
Greater Epoetin alfa (EPO) doses and short-term mortality risk among hemodialysis patients with hemoglobin levels less than 11 g/dL.
Pharmacoepidemiol Drug Saf. 2009; (10): 932-40
We examined the association between high doses of Epoetin alfa (EPO), which are used to raise and maintain hemoglobin (Hb) levels within target ranges for hemodialysis patients, and short-term mortality risk using multivariable regression and an instrumental variable (IV) analysis.
Help